BridgeMD
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS)
EU CTIS ID: 2022-502700-78-00
What this study is testing
To test the hypothesis that the high dose or the low dose of baricitinib is superior to placebo in the treatment of pediatric participants with AA
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Have severe areata alopecia (AA) for at least 1 year
- Current AA episode of at least 6 months’ duration with hair loss encompassing ≥50% of the scalp
- Current episode of severe to very severe alopecia areata of less than 8 years. - Participants who have severe AA for ≥ 8 years may be enrolled if episodes of regrowth, spontaneous or under treatment, have been observed on the affected areas over the past 8 years
You likely can't join if
- Participants must not have primarily “diffuse” type of alopecia areata
- Participants must not be currently experiencing other forms of alopecia or any other health problem that would make it difficult to see how the study drug is working on alopecia areata
- Participants must not have topical applied to scalp within 4 weeks of randomization
The study team makes the final eligibility decision.
Where it's taking place
- Japan
- Taiwan
- United States
- Argentina
- Australia
- Korea, Republic of
- Mexico
- Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Japan; Taiwan; United States; Argentina; Australia; Korea, Republic of and 2 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.